A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
|Videos|April 27, 2017
ACO Growth and Specialty Pharmacies
Author(s)Lauren Santye, Assistant Editor
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.
Advertisement
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.
Advertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5